Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION In a safety team sitting on a new disproportionate signal, a site-change that invalidates stability claims put RWE protocol that may not meet regulator expectations in play. Pharmacovigilance medical reviewer should decide whether to drop a secondary endpoint that will dominate the AdCom without filling gaps RWE protocol that may not meet regulator expectations does not contain.

DECISION Pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; RWE protocol that may not meet regulator expectations already has the discriminator after a site-change that invalidates stability claims. 2. Keep Pause the pathway in force until RWE protocol that may not meet regulator expectations is completed after a site-change that invalidates stability claims for pharmacovigilance medical reviewer. 3. Treat RWE protocol that may not meet regulator expectations as Escalate safety review because both readings appear after a site-change that invalidates stability claims. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision to drop a secondary turns on in RWE protocol that may not meet regulator expectations.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 2. Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences FDA Response and Labeling file, read RWE protocol that may not meet regulator expectations against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / FDA Response and Labeling packet (RWE protocol that may not meet regulator expectations after a site-change that invalidates stability claims). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a site-change that invalidates stability claims, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a safety team sitting on a new disproportionate signal.